Across the whole pharma sector, there are four or five stocks big one out there which are going to gain market share. So, CDMO is one space within pharma which should do well as we go along. But pharma as a whole space per se has been doing okay and we continue to believe that incrementally also pharma should continue to do well in the coming year also.
ICICI Bank, SBI among top picks which could give over 20% returns in 2025
Despite challenges in unsecured retail and microfinance segments, the banking sector’s outlook remains positive, supported by robust fundamentals and operational efficiency. Credit growth for FY25
January 4, 2025